Persistent variations of blood DNA methylation associated with treatment exposures and risk for cardiometabolic outcomes in long-term survivors of childhood cancer in the St. Jude Lifetime Cohort

Table 2 DNA methylation mediation effect of treatment exposures and CHCs

Treatment	CHC	Total effect, OR	CpG	Chromosome	Gene	Functional genomic annotation	CpG island region	% mediation
Abdominal RT	HCL	1.49	cg06963130	chr2	NA	Intergenic	Open sea	35.5
			cg21922478	chr5	ITGA1; CTD-2175A23.1	Intergenic	Open sea	23.8
			cg22976567	chr1	LMNA	5′-UTR	Open sea	22.1
			cg07403981	chr1	NA	Intergenic	Open sea	14.6
			Combined score^a					70.3
Abdominal-RT	HTG	1.5	cg19634849	chr5	CYSTM1; PFDN1	Body	Open sea	28.6
			cg13552692	chr18	CCDC102B	5′-UTR	Open sea	24.8
			cg09853238	chr6	NA	Intergenic	Open sea	17.2
			Combined score^a					54.6
Brain-RT	HTG	1.75	cg13360224	chr6	RP11-359 N11.1	Intergenic	Open sea	10.5
Brain-RT	Obesity	1.57	cg26572901	chr7	NA	Intergenic	Open sea	16.3
			cg12715065	chr6	NA	Intergenic	Open sea	14.3
			cg21163477	chr16	XYLT1	Body	Open sea	11.7
			Combined score^a					32.9
Corticosteroids	Obesity	1.56	cg22351187	chr12	KRT80	TSS1500	Open sea	14.2

Abbreviations: CHC chronic health condition, OR odds ratio, RT radiation therapy, HTG hypertriglyceridemia, and HCL hypercholesterolemia
^aCalculated by summing the DNA methylation values of CpG sites with the significant mediation effect of treatment exposures and CHCs

ISSN: 1756-994X